{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T20:29:31Z","timestamp":1795120171400,"version":"4.10.3"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.biopha.2025.118189","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T06:38:41Z","timestamp":1747982321000},"page":"118189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives"],"prefix":"10.1016","volume":"188","author":[{"given":"Seyed Saeed","family":"Tamehri Zadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanis\u0142aw","family":"Surma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118189_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.biopha.2025.118189_bib2","first-page":"3","article-title":"Prevalence and disease burden of chronic kidney disease","author":"Lv","year":"2019","journal-title":"Ren. Fibros.: Mech. Ther."},{"key":"10.1016\/j.biopha.2025.118189_bib3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"Cockwell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118189_bib4","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","article-title":"Proteinuria and the risk of developing end-stage renal disease","volume":"63","author":"Iseki","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118189_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fphar.2014.00023","article-title":"Angiopoietin-like 4 based therapeutics for proteinuria and kidney disease","volume":"5","author":"Chugh","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib6","article-title":"Expression of ANGPTL3 in children with primary nephrotic syndrome","author":"Rao","year":"1997","journal-title":"Chin. J. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/1061186X.2019.1566342","article-title":"ANGPTL3: a novel biomarker and promising therapeutic target","volume":"27","author":"Jiang","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.biopha.2025.118189_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2010.07.027","article-title":"Angiopoietin-like protein 3 regulates the motility and permeability of podocytes by altering nephrin expression in vitro","volume":"399","author":"Gao","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118189_bib9","article-title":"RNAi targeting liver Angiopoietin-like protein 3 protects from nephrotic syndrome in a rat model via amelioration of pathologic hypertriglyceridemia","author":"Zhao","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118189_bib10","article-title":"The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118189_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108549","article-title":"Podocyte protection by Angptl3 knockout via inhibiting ROS\/GRP78 pathway in LPS-induced acute kidney injury","volume":"105","author":"Ma","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-023-03214-1","article-title":"Elevated angiopoietin-like protein 3 serum levels in diabetic nephropathy patients and its association with renal function and lipid profile","volume":"24","author":"Azadi","year":"2023","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1113484","article-title":"Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children","volume":"11","author":"Wen","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.biopha.2025.118189_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fendo.2014.00004","article-title":"Angiopoietin-like proteins: a comprehensive look","volume":"5","author":"Santulli","year":"2014","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2025.118189_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1844352","article-title":"The role of ANGPTL gene family members in hepatocellular carcinoma","volume":"2022","author":"Bai","year":"2022","journal-title":"Dis. Markers"},{"key":"10.1016\/j.biopha.2025.118189_bib16","doi-asserted-by":"crossref","first-page":"41804","DOI":"10.1074\/jbc.M302861200","article-title":"Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo","volume":"278","author":"Ono","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118189_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1006\/geno.1999.6041","article-title":"Identification of a mammalian angiopoietin-related protein expressed specifically in liver","volume":"62","author":"Conklin","year":"1999","journal-title":"Genomics"},{"key":"10.1016\/j.biopha.2025.118189_bib18","doi-asserted-by":"crossref","first-page":"26410","DOI":"10.1074\/jbc.M113.501304","article-title":"Furin is the primary in vivo convertase of angiopoietin-like 3 and endothelial lipase in hepatocytes","volume":"288","author":"Essalmani","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118189_bib19","article-title":"GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118189_bib20","doi-asserted-by":"crossref","first-page":"7310","DOI":"10.3390\/ijms22147310","article-title":"Angiopoietin-like protein 3 (ANGPTL3) modulates lipoprotein metabolism and dyslipidemia","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118189_bib21","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance","volume":"58","author":"Haller","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2025.118189_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1194\/jlr.M088807","article-title":"On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity","volume":"60","author":"Kovrov","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2025.118189_bib23","doi-asserted-by":"crossref","first-page":"E493","DOI":"10.1152\/ajpendo.00195.2021","article-title":"Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8","volume":"321","author":"Sylvers-Davie","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2025.118189_bib24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbrc.2020.11.053","article-title":"Angiopoietin-like protein 4 (E40K) and ANGPTL4\/8 complex have reduced, temperature-dependent LPL-inhibitory activity compared to ANGPTL4","volume":"534","author":"Chen","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118189_bib25","doi-asserted-by":"crossref","first-page":"27561","DOI":"10.1074\/jbc.M110.144279","article-title":"Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases","volume":"285","author":"Liu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118189_bib26","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/ATVBAHA.113.301397","article-title":"Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids","volume":"33","author":"Robciuc","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2025.118189_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/01.ATV.0000252827.51626.89","article-title":"Angiopoietin-like protein3 regulates plasma HDL cholesterol through suppression of endothelial lipase","volume":"27","author":"Shimamura","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.biopha.2025.118189_bib28","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.08.031","article-title":"Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol","volume":"268","author":"Xu","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2025.118189_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tcm.2023.01.008","article-title":"ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases","volume":"34","author":"Luo","year":"2024","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib30","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1194\/jlr.M076216","article-title":"Inflammatory stress promotes the development of obesity-related chronic kidney disease via CD36 in mice","volume":"58","author":"Yang","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2025.118189_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","article-title":"Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease","volume":"2","author":"De Vries","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.biopha.2025.118189_bib32","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3390\/nu11040722","article-title":"Lipid accumulation and chronic kidney disease","volume":"11","author":"Gai","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2025.118189_bib33","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/ndt\/17.10.1751","article-title":"Fatty acids carried on albumin modulate proximal tubular cell fibronectin production: a role for protein kinase C","volume":"17","author":"Arici","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.biopha.2025.118189_bib34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3892\/ijmm.2014.1799","article-title":"Oxidized high-density lipoprotein impairs the function of human renal proximal tubule epithelial cells through CD36","volume":"34","author":"Gao","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib35","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(82)91513-6","article-title":"Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease","volume":"320","author":"Moorhead","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118189_bib36","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1681\/ASN.2011010026","article-title":"AMPK mediates the initiation of kidney disease induced by a high-fat diet","volume":"22","author":"Decleves","year":"2011","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"10.1016\/j.biopha.2025.118189_bib37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ebiom.2016.03.033","article-title":"Mass spectrometry imaging reveals elevated glomerular ATP\/AMP in diabetes\/obesity and identifies sphingomyelin as a possible mediator","volume":"7","author":"Miyamoto","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2025.118189_bib38","article-title":"Angiopoietin-like 3 induces podocyte F-actin rearrangement through integrin\/FAK\/PI3K pathway-mediated Rac1 activation","volume":"2013","author":"Lin","year":"2013"},{"key":"10.1016\/j.biopha.2025.118189_bib39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/febs.14038","article-title":"Atgl deficiency induces podocyte apoptosis and leads to glomerular filtration barrier damage","volume":"284","author":"Chen","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.biopha.2025.118189_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-015-0041-5","article-title":"Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat\/high-cholesterol diet and low-dose streptozotocin","volume":"16","author":"He","year":"2015","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-019-1052-1","article-title":"Angiopoietin-like protein 3 markedly enhanced in the hyperlipidemia related proteinuria","volume":"18","author":"Gao","year":"2019","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.biopha.2025.118189_bib42","first-page":"1","article-title":"Role of biophysics and mechanobiology in podocyte physiology","author":"Haydak","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/CS20210625","article-title":"Mechanisms of podocyte injury and implications for diabetic nephropathy","volume":"136","author":"Barutta","year":"2022","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2025.118189_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/biom12030403","article-title":"Mitochondrial oxidative stress and cell death in podocytopathies","volume":"12","author":"Zhu","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118189_bib45","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41581-020-00339-6","article-title":"Nuclear receptors in podocyte biology and glomerular disease","volume":"17","author":"Agrawal","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib46","doi-asserted-by":"crossref","first-page":"F532","DOI":"10.1152\/ajprenal.00316.2023","article-title":"Renin-angiotensin system-mediated nitric oxide signaling in podocytes","volume":"327","author":"Semenikhina","year":"2024","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118189_bib47","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.kint.2016.09.042","article-title":"Podocyte-specific chemokine (CC motif) receptor 2 overexpression mediates diabetic renal injury in mice","volume":"91","author":"You","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118189_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40348-023-00157-3","article-title":"New insights into the immune functions of podocytes: the role of complement","volume":"10","author":"Bruno","year":"2023","journal-title":"Mol. Cell. Pediatr."},{"key":"10.1016\/j.biopha.2025.118189_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.kint.2023.10.035","article-title":"Complement activation and effector pathways in membranous nephropathy","volume":"105","author":"Kistler","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118189_bib50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41581-020-0329-y","article-title":"Complexities of the glomerular basement membrane","volume":"17","author":"Naylor","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41392-022-00934-y","article-title":"Notch signaling pathway: architecture, disease, and therapeutics","volume":"7","author":"Zhou","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118189_bib52","article-title":"Excessive activation of notch signaling in macrophages promote kidney inflammation, fibrosis, and necroptosis","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118189_bib53","doi-asserted-by":"crossref","first-page":"F877","DOI":"10.1152\/ajprenal.00415.2023","article-title":"Mechanisms and implications of podocyte autophagy in chronic kidney disease","volume":"326","author":"Njeim","year":"2024","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118189_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13850","article-title":"A critical role of the podocyte cytoskeleton in the pathogenesis of glomerular proteinuria and autoimmune podocytopathies","volume":"235","author":"Ye","year":"2022","journal-title":"Acta Physiol."},{"key":"10.1016\/j.biopha.2025.118189_bib55","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00047.x","article-title":"Podocyte injuries exacerbate mesangial proliferative glomerulonephritis","volume":"60","author":"Morioka","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118189_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.771931","article-title":"Controversies in podocyte loss: death or detachment?","volume":"9","author":"Yin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118189_bib57","doi-asserted-by":"crossref","first-page":"F515","DOI":"10.1152\/ajprenal.00080.2022","article-title":"Podocytes are lost from glomeruli before completing apoptosis","volume":"323","author":"Yamamoto","year":"2022","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118189_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.991756","article-title":"New insights into proteinuria\/albuminuria","volume":"13","author":"Comper","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2025.118189_bib59","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1038\/s41467-022-33748-1","article-title":"A slit-diaphragm-associated protein network for dynamic control of renal filtration","volume":"13","author":"Kocylowski","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118189_bib60","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1681\/ASN.2011121206","article-title":"Podocyte-specific loss of Cdc42 leads to congenital nephropathy","volume":"23","author":"Scott","year":"2012","journal-title":"J. Am. Soc. Nephrol.: JASN"},{"key":"10.1016\/j.biopha.2025.118189_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-015-0036-8","article-title":"The role of alpha-actinin-4 in human kidney disease","volume":"5","author":"Feng","year":"2015","journal-title":"Cell Biosci."},{"key":"10.1016\/j.biopha.2025.118189_bib62","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/pr.2015.38","article-title":"A novel role of angiopoietin-like-3 associated with podocyte injury","volume":"77","author":"Liu","year":"2015","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.biopha.2025.118189_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/135608","article-title":"Angiopoietin-like 3 induces podocyte F-Actin rearrangement through integrin \u03b1V\u03b23\/FAK\/PI3K pathway-mediated rac1 activation","volume":"2013","author":"Lin","year":"2013","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.biopha.2025.118189_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-019-1383-1","article-title":"Angiopoietin-like-3 knockout protects against glomerulosclerosis in murine adriamycin-induced nephropathy by attenuating podocyte loss","volume":"20","author":"Dai","year":"2019","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib65","article-title":"Effect of nephropathy prescription I on the expression of angptl3 and podocyte-associated protein in mice with adriamycin-induced nephropathy","volume":"2022","author":"Zhang","year":"2022","journal-title":"Evid. -Based Complement. Altern. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.627800","article-title":"Integrin, exosome and kidney disease","volume":"11","author":"Shen","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.biopha.2025.118189_bib67","first-page":"1","article-title":"Integrins in the kidney\u2014beyond the matrix","author":"Bock","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib68","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.lab.2005.08.011","article-title":"Reduced podocyte expression of \u03b13\u03b21 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats","volume":"147","author":"Chen","year":"2006","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11892-016-0748-0","article-title":"The role of mitochondria in diabetic kidney disease","volume":"16","author":"Hallan","year":"2016","journal-title":"Curr. Diabetes Rep."},{"key":"10.1016\/j.biopha.2025.118189_bib70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-015-0034-4","article-title":"A vital role for Angptl3 in the PAN-induced podocyte loss by affecting detachment and apoptosis in vitro","volume":"16","author":"Dai","year":"2015","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib71","doi-asserted-by":"crossref","first-page":"41179","DOI":"10.1074\/jbc.M400292200","article-title":"Angiopoietin-3 is tethered on the cell surface via heparan sulfate proteoglycans","volume":"279","author":"Xu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118189_bib72","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1159\/000313829","article-title":"Expression of angiopoietin-like 3 associated with puromycin-induced podocyte damage","volume":"115","author":"Jia","year":"2010","journal-title":"Nephron Exp. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1038073","article-title":"Cellular phenotypic transitions in diabetic nephropathy: an update","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib74","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/0886022X.2017.1313164","article-title":"Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update","volume":"39","author":"Ying","year":"2017","journal-title":"Ren. Fail."},{"key":"10.1016\/j.biopha.2025.118189_bib75","article-title":"The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118189_bib76","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3389\/fphar.2019.01192","article-title":"Inflammation in renal diseases: new and old players","volume":"10","author":"Andrade-Oliveira","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib77","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1497449","article-title":"Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment","volume":"2021","author":"Samsu","year":"2021","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/j.biopha.2025.118189_bib78","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s00011-024-01941-1","article-title":"Simultaneously blocking ANGPTL3 and IL-1\u03b2 for the treatment of atherosclerosis through lipid-lowering and anti-inflammation","volume":"73","author":"Wang","year":"2024","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.biopha.2025.118189_bib79","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jare.2024.05.011","article-title":"ANGPTL3 accelerates atherosclerotic progression via direct regulation of M1 macrophage activation in plaque","volume":"70","author":"Zhang","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.biopha.2025.118189_bib80","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2022.06.173","article-title":"ANGPTL3 induces a proinflammatory response in THP-1 derived macrophages","volume":"355","author":"Rossi","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.biopha.2025.118189_bib81","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","article-title":"Mitochondrial dysfunction: mechanisms and advances in therapy","volume":"9","author":"Zong","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118189_bib82","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nrneph.2017.107","article-title":"Mitochondrial energetics in the kidney","volume":"13","author":"Bhargava","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib83","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.kint.2022.08.022","article-title":"Phosphoglycerate mutase 5 initiates inflammation in acute kidney injury by triggering mitochondrial DNA release by dephosphorylating the pro-apoptotic protein Bax","volume":"103","author":"Li","year":"2023","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118189_bib84","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1681\/ASN.2016050519","article-title":"Targeting mTOR signaling can prevent the progression of FSGS","volume":"28","author":"Zschiedrich","year":"2017","journal-title":"J. Am. Soc. Nephrol. JASN"},{"key":"10.1016\/j.biopha.2025.118189_bib85","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrneph.2018.9","article-title":"Mitochondrial dysfunction in diabetic kidney disease","volume":"14","author":"Forbes","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.biopha.2025.118189_bib86","article-title":"Podocyte injury in diabetic kidney disease: a focus on mitochondrial dysfunction","volume":"10","author":"Liu","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2025.118189_bib87","doi-asserted-by":"crossref","first-page":"E1249","DOI":"10.1073\/pnas.1717420115","article-title":"Increased thermogenesis by a noncanonical pathway in ANGPTL3\/8-deficient mice","volume":"115","author":"Banfi","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118189_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-022-01632-y","article-title":"ANGPTL3 impacts proteinuria and hyperlipidemia in primary nephrotic syndrome","volume":"21","author":"Zhong","year":"2022","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.biopha.2025.118189_bib89","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.3390\/ijms20205055","article-title":"Exploration and development of PPAR modulators in health and disease: an update of clinical evidence","volume":"20","author":"Cheng","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118189_bib90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41572-020-0196-7","article-title":"Podocytopathies","volume":"6","author":"Kopp","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2025.118189_bib91","article-title":"The role of peroxisome proliferator-activated receptors in kidney diseases","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib92","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1194\/jlr.M200367-JLR200","article-title":"Regulation of the angiopoietin-like protein 3 gene by LXR","volume":"44","author":"Kaplan","year":"2003","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.biopha.2025.118189_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112753","article-title":"PPAR\u03b1 agonist exerts protective effects in podocyte injury via inhibition of the ANGPTL3 pathway","volume":"407","author":"Han","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.biopha.2025.118189_bib94","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s11883-023-01142-x","article-title":"Fixed combination for the treatment of dyslipidaemia","volume":"25","author":"Ferri","year":"2023","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.biopha.2025.118189_bib95","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3389\/fphar.2019.00444","article-title":"Current development of siRNA bioconjugates: from research to the clinic","volume":"10","author":"Chernikov","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2023.07.008","article-title":"The promise of PCSK9 and lipoprotein (a) as targets for gene silencing therapies","author":"Chan","year":"2023","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2025.118189_bib97","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA in dyslipidemias: JACC state-of-the-art review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118189_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104413","article-title":"A new dawn for managing dyslipidemias: the era of RNA-based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2025.118189_bib99","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41569-023-00892-0","article-title":"International atherosclerosis society guidance for implementing best practice in the care of familial hypercholesterolaemia","volume":"20","author":"Watts","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.biopha.2025.118189_bib100","doi-asserted-by":"crossref","unstructured":"Surma S., Shapiro M.D. and Banach M. Breaking New Ground in Lipid Management: Insights from the 2024 American College of Cardiology Scientific Sessions. 2024:107246.","DOI":"10.1016\/j.phrs.2024.107246"},{"key":"10.1016\/j.biopha.2025.118189_bib101","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for mixed hyperlipidemia","author":"Rosenson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib102","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41419-022-05313-7","article-title":"Anti-ANGPTL3-FLD monoclonal antibody treatment ameliorates podocyte lesions through attenuating mitochondrial damage","volume":"13","author":"Lv","year":"2022","journal-title":"Cell death Dis."},{"key":"10.1016\/j.biopha.2025.118189_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109656","article-title":"Minnelide combined with Angptl3 knockout completely protects mice with adriamycin nephropathy via suppression of TGF-\u03b21-Smad2 and p53 pathways","volume":"115","author":"Ji","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib104","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat measures of lipoprotein (a) molar concentration and cardiovascular risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.118189_bib105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbrc.2019.06.065","article-title":"Anti-proteinuria effect of antibody against ANGPTL3 coil-coiled domain on adriamycin-induced nephropathy in mice","volume":"516","author":"Han","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2025.118189_bib106","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17512433.2022.2047934","article-title":"Evinacumab for the treatment of homozygous familial hypercholesterolemia","volume":"15","author":"Gao","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib107","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/ph15070839","article-title":"New therapeutic approaches in treatment of dyslipidaemia\u2014A narrative review","volume":"15","author":"Mer\u0107ep","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.biopha.2025.118189_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1475198","article-title":"Angiopoietin-like protein 4 dysregulation in kidney diseases: a promising biomarker and therapeutic target","volume":"15","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118189_bib109","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14779072.2021.1955349","article-title":"Evinacumab for treatment of familial hypercholesterolemia","volume":"19","author":"Warden","year":"2021","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.biopha.2025.118189_bib110","article-title":"DIPA-CRISPR is a simple and accessible method for insect gene editing","volume":"2","author":"Shirai","year":"2022","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.biopha.2025.118189_bib111","doi-asserted-by":"crossref","first-page":"8422","DOI":"10.3390\/ijms22168422","article-title":"Harnessing the potential of CRISPR\/Cas in atherosclerosis: disease modeling and therapeutic applications","volume":"22","author":"Siew","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118189_bib112","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/ki.2013.354","article-title":"Exome sequencing and in vitro studies identified podocalyxin as a candidate gene for focal and segmental glomerulosclerosis","volume":"85","author":"Barua","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118189_bib113","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1038\/ncomms9715","article-title":"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids","volume":"6","author":"Freedman","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118189_bib114","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118189_bib115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/metabo11120857","article-title":"CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities","volume":"11","author":"Walker","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.biopha.2025.118189_bib116","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","volume":"147","author":"Lee","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.118189_bib117","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-023-35886-6","article-title":"Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing","volume":"14","author":"Tao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118189_bib118","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1021\/acs.accounts.3c00279","article-title":"Development of CRISPR\/Cas delivery systems for in vivo precision genome editing","volume":"56","author":"Chen","year":"2023","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.biopha.2025.118189_bib119","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1053\/j.ajkd.2018.02.347","article-title":"CRISPR gene editing in the kidney","volume":"71","author":"Cruz","year":"2018","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.biopha.2025.118189_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11081286","article-title":"World experience in immunization against noncommunicable diseases: successes and vectors for further development","volume":"11","author":"Kashutina","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.biopha.2025.118189_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114469","article-title":"Peptide-based anti-PCSK9 vaccines-an approach for long-term LDLc management","volume":"9","author":"Galabova","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118189_bib122","doi-asserted-by":"crossref","unstructured":"A. Sahebkar, A.A. Momtazi-Borojeni, M. Banach, Eur Heart J 42 (2021) 4007\u20134010.","DOI":"10.1093\/eurheartj\/ehab299"},{"key":"10.1016\/j.biopha.2025.118189_bib123","article-title":"Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes","volume":"12","author":"Myers","year":"2019","journal-title":"Circ.: Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.biopha.2025.118189_bib124","article-title":"Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia","volume":"2","author":"Fukami","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib125","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1016\/j.vaccine.2021.08.077","article-title":"A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice","volume":"39","author":"Fowler","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2025.118189_bib126","first-page":"1098","article-title":"Hepatic inhibition of ANGPTL3 mimics the molecular hallmarks of hypothyroidism","volume":"Arteriosclr Thromb Vasc Biol 44","author":"Taebnia","year":"2024"},{"key":"10.1016\/j.biopha.2025.118189_bib127","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12967-024-05032-x","article-title":"ANGPTL3 is a novel HDL component that regulates HDL function","volume":"22","author":"Yang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118189_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11883-021-00972-x","article-title":"Monoclonal antibodies in the management of familial hypercholesterolemia: focus on PCSK9 and ANGPTL3 inhibitors","volume":"23","author":"Pirillo","year":"2021","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.biopha.2025.118189_bib129","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41598-018-36581-z","article-title":"The association between genetic variants of angiopoietin-like 3 and risk of diabetes mellitus is modified by dietary factors in Koreans","volume":"9","author":"Park","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.118189_bib130","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7504798","article-title":"Research progress on the pathological mechanisms of podocytes in diabetic nephropathy","volume":"2020","author":"Zhang","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.biopha.2025.118189_bib131","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/jcm12010168","article-title":"Evinacumab, an ANGPTL3 Inhibitor, in the treatment of dyslipidemia","volume":"12","author":"Sosnowska","year":"2022","journal-title":"J. Clin. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500383X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500383X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:48:03Z","timestamp":1758124083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500383X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":131,"alternative-id":["S075333222500383X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118189","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ANGPTL3 vital role in different kidney diseases. Current knowledge and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118189"}}